Post audit review: GlaxoSmithKline
Oversight record (audit, advice, assessment or regulatory action) from NHS England data sharing audits. Evidence status: source reported.
- Organisation
- GlaxoSmithKline
- Published
- 2022-05-01
- Source reference
- 2022-post-audit-review-gsk
- Jurisdiction
- England
- Licence
- Open Government Licence v3.0 (NHS England)
Post audit review of GlaxoSmithKline by NHS England · Audit between 9 and 19 August 2021 · Risk assigned: Low · 10 agreement nonconformities, 3 organisation nonconformities, 3 observations, 8 opportunities for improvement · Agreement DARS-NIC-297783-V4P6H
Source: https://digital.nhs.uk/services/data-access-request-service-dars/data-sharing-audits/2022/post-audit-review-gsk. Captured 2026-10-30.
Limitations: An audit report as NHS England publishes it. Findings are against a sample of the organisation's activities and the contracts in force at the time; an audit with no findings recorded here may still have had some, as older reports state them in tables or by highlighting that are not read. Publication is given to the month only. The report's text is not stored; follow the link to read it.